Update shared on 07 Dec 2025
Narrative Update on Jamjoom Pharmaceuticals Factory
Analysts have maintained their fair value price target for Jamjoom Pharmaceuticals Factory at SAR 169.63. This reflects stable expectations for revenue growth, profit margins, and future valuation multiples despite recent market volatility.
What's in the News
- A board meeting is scheduled for October 23, 2025, to review and discuss Jamjoom Pharmaceuticals Factory's financial results for Q3 2025 (company filing).
Valuation Changes
- Consensus Analyst Price Target: Fair value remains unchanged at SAR 169.63, indicating no revision in analysts' central valuation view.
- Discount Rate: The discount rate is stable at 19.11%, suggesting no change in perceived risk or required rate of return.
- Revenue Growth: The revenue growth assumption is effectively unchanged at approximately 12.97%, with only negligible rounding differences.
- Net Profit Margin: The net profit margin outlook remains steady at about 30.62%, indicating no material change in profitability expectations.
- Future P/E: The future P/E multiple is unchanged at roughly 31.21x, reflecting consistent expectations for the company’s earnings valuation.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.